October 4, 2017
The Japan arm of US pharma giant Merck is to postpone the launch of its hypercholesterolemia agent Atozet (ezetimibe + atorvastatin), a fixed-dose combo of Zetia and Lipitor approved last week, as a June cyberattack against the company is taking...read more